

Atanas Ignatov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6705280/publications.pdf>

Version: 2024-02-01

79
papers

2,069
citations

201385

27
h-index

264894

42
g-index

83
all docs

83
docs citations

83
times ranked

2704
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 457-466. | 1.1 | 144 |
| 2 | Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 87-96. | 1.1 | 138 |
| 3 | Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 465-470. | 1.1 | 131 |
| 4 | RANTES stimulates Ca ²⁺ mobilization and inositol trisphosphate (IP ₃) formation in cells transfected with G protein-coupled receptor 75. <i>British Journal of Pharmacology</i> , 2006, 149, 490-497. | 2.7 | 89 |
| 5 | GPER-1 acts as a tumor suppressor in ovarian cancer. <i>Journal of Ovarian Research</i> , 2013, 6, 51. | 1.3 | 80 |
| 6 | Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, 725-733. | 1.6 | 80 |
| 7 | Role of tumour-free margin distance for loco-regional control in vulvar cancer – a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study. <i>European Journal of Cancer</i> , 2016, 69, 180-188. | 1.3 | 64 |
| 8 | Patterns of breast cancer relapse in accordance to biological subtype. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1347-1355. | 1.2 | 60 |
| 9 | Sphingosine-1-phosphate is a high-affinity ligand for the G protein-coupled receptor GPR6 from mouse and induces intracellular Ca ²⁺ release by activating the sphingosine-kinase pathway. <i>Biochemical and Biophysical Research Communications</i> , 2003, 311, 329-336. | 1.0 | 57 |
| 10 | GPER functions as a tumor suppressor in triple-negative breast cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 713-723. | 1.2 | 56 |
| 11 | GPER functions as a tumor suppressor in MCF-7 and SK-BR-3 breast cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 663-671. | 1.2 | 43 |
| 12 | APC promoter hypermethylation is an early event in endometrial tumorigenesis. <i>Cancer Science</i> , 2010, 101, 321-327. | 1.7 | 42 |
| 13 | GPER-1 Expression Decreases During Breast Cancer Tumorigenesis. <i>Cancer Investigation</i> , 2013, 31, 309-315. | 0.6 | 41 |
| 14 | Survival advantage of lymphadenectomy in endometrial cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1051-1060. | 1.2 | 41 |
| 15 | Loss of HER2 after HER2-targeted treatment. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 401-408. | 1.1 | 41 |
| 16 | Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen. <i>Cancers</i> , 2020, 12, 1766. | 1.7 | 41 |
| 17 | Lymph node micrometastases and outcome of endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 154, 475-479. | 0.6 | 40 |
| 18 | Adjuvant radiotherapy for vulvar cancer with close or positive surgical margins. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 489-495. | 1.2 | 37 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | P16 alterations increase the metastatic potential of endometrial carcinoma. <i>Gynecologic Oncology</i> , 2008, 111, 365-371. | 0.6 | 35 |
| 20 | Accuracy of ultrasound-guided breast-conserving surgery in the determination of adequate surgical margins. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 129-136. | 1.1 | 35 |
| 21 | G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 121-127. | 1.1 | 34 |
| 22 | Role of GPR30 in endometrial pathology after tamoxifen for breast cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 203, 595.e9-595.e16. | 0.7 | 33 |
| 23 | <i>BRCA1</i> Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1190-1203. | 3.0 | 32 |
| 24 | <i>BRCA1</i> promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 205-212. | 1.1 | 31 |
| 25 | Accumulation of the advanced glycation end product carboxymethyl lysine in breast cancer is positively associated with estrogen receptor expression and unfavorable prognosis in estrogen receptor-negative cases. <i>Histochemistry and Cell Biology</i> , 2017, 147, 625-634. | 0.8 | 30 |
| 26 | Tumor characteristics and therapy of elderly patients with breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1109-1116. | 1.2 | 29 |
| 27 | Management of elderly women with endometrial cancer. <i>Gynecologic Oncology</i> , 2017, 146, 519-524. | 0.6 | 29 |
| 28 | G protein-coupled estrogen receptor (GPER) expression in endometrial adenocarcinoma and effect of agonist G-1 on growth of endometrial adenocarcinoma cell lines. <i>Steroids</i> , 2013, 78, 1087-1091. | 0.8 | 27 |
| 29 | Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis. <i>British Journal of Cancer</i> , 2019, 120, 301-305. | 2.9 | 27 |
| 30 | Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 337-341. | 1.2 | 26 |
| 31 | Ultrasonography-Guided Breast-Conserving Surgery Is Superior to Palpation-Guided Surgery for Palpable Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 40-45. | 1.1 | 25 |
| 32 | Management of small T1a/b breast cancer by tumor subtype. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 111-118. | 1.1 | 25 |
| 33 | Management of elderly women with cervical cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 961-967. | 1.2 | 25 |
| 34 | Ultrasound-Guided Versus Wire-Guided Breast-Conserving Surgery for Nonpalpable Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, e1-e6. | 1.1 | 23 |
| 35 | <i>BRCA1</i> promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1457-1463. | 1.2 | 22 |
| 36 | Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 357-364. | 1.1 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | High neuronatin (NNAT) expression is associated with poor outcome in breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 23-30. | 1.4 | 22 |
| 38 | p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft GynÄkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 595.e1-595.e11. | 0.7 | 21 |
| 39 | Ovarian metastasis in patients with endometrial cancer: risk factors and impact on survival. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1103-1107. | 1.2 | 18 |
| 40 | Endometrial cancer subtypes are associated with different patterns of recurrence. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2011-2017. | 1.2 | 18 |
| 41 | Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis. <i>British Journal of Cancer</i> , 2020, 123, 33-37. | 2.9 | 17 |
| 42 | <i>GPER</i> Promoter Methylation Controls GPER Expression in Breast Cancer Patients. <i>Cancer Investigation</i> , 2017, 35, 100-107. | 0.6 | 16 |
| 43 | Predicting the course of disease in recurrent vulvar cancer â€“ A subset analysis of the AGO-CaRE-1 study. <i>Gynecologic Oncology</i> , 2019, 154, 571-576. | 0.6 | 15 |
| 44 | GPER-1 expression is associated with a decreased response rate to primary tamoxifen therapy of breast cancer patients. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 565-571. | 0.8 | 15 |
| 45 | Oxidative stress and glyoxalase I activity mediate dicarbonyl toxicity in MCF-7 mamma carcinoma cells and a tamoxifen resistant derivative. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2016, 1860, 1272-1280. | 1.1 | 14 |
| 46 | G protein-coupled estrogen receptor 1 (GPER-1) and agonist G-1 inhibit growth of ovarian cancer cells by activation of anti-tumoral transcriptome responses: impact of GPER-1 mRNA on survival. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3175-3188. | 1.2 | 13 |
| 47 | Adjuvant hysterectomy after radiochemotherapy for locally advanced cervical cancer. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 1048-1055. | 1.0 | 12 |
| 48 | Adjuvant radiotherapy and local recurrence in vulvar cancer â€“ a subset analysis of the AGO-CaRE-1 study. <i>Gynecologic Oncology</i> , 2022, 164, 68-75. | 0.6 | 12 |
| 49 | Puerperal mastitis in the past decade: results of a single institution analysis. <i>Archives of Gynecology and Obstetrics</i> , 2019, 300, 1637-1644. | 0.8 | 10 |
| 50 | Comparison of survival of patients with endometrial cancer undergoing sentinel node biopsy alone or systematic lymphadenectomy. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 995-1000. | 0.8 | 9 |
| 51 | Minimal-invasive or open approach for surgery of early cervical cancer: the treatment center matters. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 503-510. | 0.8 | 9 |
| 52 | Laparoscopic-assisted vaginal hysterectomy versus vaginal hysterectomy for benign uterine diseases: a prospective, randomized, multicenter, double-blind trial (LAVA). <i>Archives of Gynecology and Obstetrics</i> , 2018, 297, 479-485. | 0.8 | 8 |
| 53 | Impact of nodal status and treatment strategy on overall survival in advanced stage cervical cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1369-1376. | 1.2 | 8 |
| 54 | Time resolved gene expression analysis during tamoxifen adaption of MCF-7 cells identifies long non-coding RNAs with prognostic impact. <i>RNA Biology</i> , 2019, 16, 661-674. | 1.5 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Should the hyperechogenic halo around malignant breast lesions be included in the measurement of tumor size?. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 311-317. | 1.1 | 7 |
| 56 | BCL3 expression is strongly associated with the occurrence of breast cancer relapse under tamoxifen treatment in a retrospective cohort study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 529-541. | 1.4 | 7 |
| 57 | Reproductive Outcome of Women with Rare Müllerian Anomaly: Report of 2 Cases. <i>Journal of Minimally Invasive Gynecology</i> , 2008, 15, 502-504. | 0.3 | 6 |
| 58 | Hormone receptor status does not alter the effect of trastuzumab in breast cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, 349-355. | 1.6 | 6 |
| 59 | Systematic lymphadenectomy in early stage endometrial cancer. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 231-239. | 0.8 | 6 |
| 60 | Expression of p53 and selected proliferative markers (Ki-67, MCM3, PCNA, and topoisomerase II β) in borderline ovarian tumors: Correlation with clinicopathological features. <i>Histology and Histopathology</i> , 2018, 33, 171-179. | 0.5 | 6 |
| 61 | Protective effect of pre-operative conization in patients undergoing surgical treatment for early-stage cervical cancer. <i>Gynecologic Oncology</i> , 2022, 166, 57-60. | 0.6 | 6 |
| 62 | Endometrial cancer after ulipristal acetate for uterine fibroma. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 219, 134. | 0.5 | 5 |
| 63 | A comparison of tumour size measurements with palpation, ultrasound and mammography in male breast cancer: first results of the prospective register study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 381-387. | 1.2 | 5 |
| 64 | <i>STRN-ALK</i> Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy. <i>JCO Precision Oncology</i> , 2021, 5, 1507-1513. | 1.5 | 5 |
| 65 | Comparative Study of Surgical Margins and Cosmetic Outcome in Lumpectomy versus Segmental Resection in Breast Cancer. <i>European Surgical Research</i> , 2011, 47, 231-239. | 0.6 | 4 |
| 66 | Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 715-727. | 1.1 | 4 |
| 67 | Contralateral lymph node metastases in patients with vulvar cancer and unilateral sentinel lymph node metastases. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 1520-1525. | 1.3 | 4 |
| 68 | Risk factors and temporal patterns of recurrences in patients with vulvar cancer: implications for follow-up intervals and duration. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 803-810. | 1.2 | 4 |
| 69 | Glyoxalase 1 expression analysis by immunohistochemistry in breast cancer. <i>Pathology Research and Practice</i> , 2020, 216, 153257. | 1.0 | 3 |
| 70 | Clinical Implications of Growth Pattern and Extension of Tumor-Associated Intraductal Carcinoma of the Breast. <i>Clinical Breast Cancer</i> , 2015, 15, 227-233. | 1.1 | 2 |
| 71 | Peritoneal closure during laparoscopic supracervical hysterectomy. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 785-789. | 0.8 | 2 |
| 72 | Vaginal brachytherapy for endometrial cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1523-1530. | 1.2 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | The predictive potential of Neuronatin for neoadjuvant chemotherapy of breast cancer. <i>Cancer Biomarkers</i> , 2021, 32, 161-173. | 0.8 | 2 |
| 74 | Perinatal and maternal outcomes at term in low-risk pregnancies according to NICE criteria: comparison between a tertiary obstetrical hospital and midwife-attended units. <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 223-229. | 0.8 | 1 |
| 75 | The impact of G protein-coupled oestrogen receptor 1 on male breast cancer: a retrospective analysis. <i>Wspolczesna Onkologia</i> , 2021, 25, 204-212. | 0.7 | 1 |
| 76 | The importance of the cerebroplacental ratio for the prognosis of neonatal outcome in AGA fetuses. <i>Archives of Gynecology and Obstetrics</i> , 2023, 307, 311-317. | 0.8 | 1 |
| 77 | Endometriumkarzinom bei der alten und geriatrischen Patientin. , 2017, , 1-7. | | 0 |
| 78 | Endometriumkarzinom bei der alten und geriatrischen Patientin. , 2018, , 429-435. | | 0 |
| 79 | Survival Advantage of Lymphadenectomy in Patients with Ovarian Cancer. <i>Cancer Investigation</i> , 2022, , 1-17. | 0.6 | 0 |